NCT02426684View on ClinicalTrials.gov

Ides in Highly Sensitized (HS) Patients Awaiting Kidney Transplantation

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

June 16, 2015

Primary Completion Date

November 10, 2017

Study Completion Date

November 10, 2017

Conditions
Renal Disease
Interventions
DRUG

IdeS® (Imlifidase)

0.24mg/kg IdeS

Trial Locations (1)

90048

Cedars-Sinai Medical Center, Los Angeles

Sponsors

Collaborators (1)

Hansa Biopharma AB
All Listed Sponsors
collaborator

Hansa Biopharma AB

INDUSTRY

lead

Cedars-Sinai Medical Center

OTHER

NCT02426684 - Ides in Highly Sensitized (HS) Patients Awaiting Kidney Transplantation | Biotech Hunter | Biotech Hunter